Detection and genotyping of human papillomavirus by five assays according to cytologic results

Journal of Virological Methods

Volumn 187, Issue 1, 2013, Pages 79-84

  Choi, Jonghyeon ^a,b   Park, Yongjung ^a   Lee, Eun Hee ^c   Kim, Sinyoung ^d   Kim, Jeong Ho ^a   Kim, Hyon Suk ^a  

^a Yonsei University College of Medicine   (South Korea)

^b NeoDin Medical Institute   (South Korea)

^c Green Cross Reference Laboratory   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

Genotyping; Human papillomavirus (HPV); Hybrid capture assay; Liquid beads microarray; Peptide nucleic acid based array; Real time PCR

Indexed keywords

ARTICLE; ASSAY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA SEQUENCE; ENZYME IMMUNOASSAY; FEMALE; GENOTYPE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MICROARRAY ANALYSIS; NUCLEIC ACID HYBRIDIZATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

BASE SEQUENCE; DNA, VIRAL; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 84871805591     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2012.09.005     Document Type: Article

References (30)

1. Bosch F.X., Burchell A.N., Schiffman M., Giuliano A.R., de Sanjose S., Bruni L., Tortolero-Luna G., Kjaer S.K., Munoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26(Suppl. 10):K1-K16.
2. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., Benbrahim-Tallaa L., Guha N., Freeman C., Galichet L., Cogliano V. A review of human carcinogens - Part B: biological agents. Lancet Oncology 2009, 10:321-322.
3. Carozzi F.M., Burroni E., Bisanzi S., Puliti D., Confortini M., Giorgi Rossi P., Sani C., Scalisi A., Chini F. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting. Journal of Clinical Microbiology 2011, 49:1446-1451.
4. Choi J.J., Kim C., Park H. Peptide nucleic acid-based array for detecting and genotyping human papillomaviruses. Journal of Clinical Microbiology 2009, 47:1785-1790.
5. Clifford G.M., Rana R.K., Franceschi S., Smith J.S., Gough G., Pimenta J.M. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiology Biomarkers and Prevention 2005, 14:1157-1164.
6. Cox J.T. History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. Journal of Clinical Virology 2009, 45(Suppl. 1):S3-S12.
7. Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., Ronco G., Mayrand M.H., Dillner J., Meijer C.J. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008, 26(Suppl. 10):K29-K41.
8. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., Szarewski A., Birembaut P., Kulasingam S., Sasieni P., Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. International Journal of Cancer 2006, 119:1095-1101.
9. Department of Reproductive Health and Research, 2008. Cervical cancer, human papillomavirus (HPV), and HPV vaccines; key points for policy-makers and health professionals. World Health Organization 08.14.
10. Eom J.H., Park S.B., Zhang B.T. Genetic mining of DNA sequence structures for effective classification of the risk types of human papillomavirus (HPV). Lecturer Notes in Computer Science 2004, 3316:1334-1343.
11. Fakhry C., Gillison M.L. Clinical implications of human papillomavirus in head and neck cancers. Journal of Clinical Oncology 2006, 24:2606-2611.
12. Franceschi S., Cuzick J., Herrero R., Dillner J., Wheeler C.M. EUROGIN 2008 roadmap on cervical cancer prevention. International Journal of Cancer 2009, 125:2246-2255.
13. Gustafsson L., Ponten J., Bergstrom R., Adami H.O. International incidence rates of invasive cervical cancer before cytological screening. International Journal of Cancer 1997, 71:159-165.
14. Gustafsson L., Ponten J., Zack M., Adami H.O. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes and Control 1997, 8:755-763.
15. Kovacic M.B., Castle P.E., Herrero R., Schiffman M., Sherman M.E., Wacholder S., Rodriguez A.C., Hutchinson M.L., Bratti M.C., Hildesheim A., Morales J., Alfaro M., Burk R.D. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Research 2006, 66:10112-10119.
16. Li N., Franceschi S., Howell-Jones R., Snijders P.J., Clifford G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. International Journal of Cancer 2011, 128:927-935.
17. Lorincz A.T. Hybrid capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening. Journal of Obstetrics and Gynaecology Research 1996, 22:629-636.
18. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., Arbyn M., Bosch F.X., Cuzick J., Dillner J., Heideman D.A., Snijders P.J. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. International Journal of Cancer 2009, 124:516-520.
19. Nayar R., Solomon D. Second edition of 'The Bethesda System for reporting cervical cytology' - atlas, website, and Bethesda interobserver reproducibility project. Cytojournal 2004, 1:4.
20. Parkin D.M., Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006, 24(Suppl. 3). S3/11-S3/25.
21. Poljak M., Brencic A., Seme K., Vince A., Marin I.J. Comparative evaluation of first- and second-generation digene hybrid capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer. Journal of Clinical Microbiology 1999, 37:796-800.
22. Poljak M., Ostrbenk A., Seme K., Ucakar V., Hillemanns P., Bokal E.V., Jancar N., Klavs I. Comparison of clinical and analytical performance of the Abbott RealTime high risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening. Journal Clinical Microbiology 2011, 49:1721-1729.
23. Report of the GAVI-UNFPA-WHO Meeting, 2009. Strengthening cervical cancer prevention and control. World Health Organization 10.13.
24. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007, 370:890-907.
25. Schiffman M., Wentzensen N., Wacholder S., Kinney W., Gage J.C., Castle P.E. Human papillomavirus testing in the prevention of cervical cancer. Journal of the National Cancer Institute 2011, 103:368-383.
26. Schiffman M., Wheeler C.M., Castle P.E. Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities. Journal of Infectious Diseases 2002, 186:1169-1172.
27. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., Clifford G.M. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. International Journal of Cancer 2007, 121:621-632.
28. Terry G., Ho L., Londesborough P., Cuzick J., Mielzynska-Lohnas I., Lorincz A. Detection of high-risk HPV types by the hybrid capture 2 test. Journal of Medical Virology 2001, 65:155-162.
29. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions triage study (ALTS) group. Journal of the National Cancer Institute 2000, 92:397-402. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study Group.
30. Wong O.G., Lo C.K., Szeto E., Cheung A.N. Efficacy of Abbott RealTime High Risk HPV test in evaluation of atypical squamous cells of undetermined significance from an Asian screening population. Journal of Clinical Virology 2011, 51:136-138.